Litigation Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-01-28 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:1 Patent Infringement | Assigned To | Jennifer L. Hall |
| Jury Demand | Defendant | Referred To | |
| Parties | CADILA HEALTHCARE LIMITED | ||
| Patents | 10,543,179; 9,187,405 | ||
| Attorneys | Darish Huynh | ||
| Firms | Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-01-28 | 1 | Complaint | mg, prior to expiration of U.S. Patent No. 10,543,179 (“the ’179 patent”). ME1 32500579v.1 Case 1…. This is an action for patent infringement arising under the patent laws of the United States, …prior to the expiration of U.S. Patent No. 9,187,405 (“the ’405 patent”). 9. In …)(IV), with respect to the ’405 patent asserting that the ’405 patent is invalid, unenforceable, and/…20 Page 7 of 40 PageID #: 7 patent asserting that the ’405 patent is invalid, unenforceable, and/or | External link to document |
| 2022-05-17 | 125 | Notice of Service | ' Invalidity Contentions Regarding U.S. Patent No. 10,543,179 filed by Novartis Pharmaceuticals Corporation… 28 January 2020 1:20-cv-00133 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2022-06-24 | 132 | Notice of Service | HECs Invalidity Contentions Regarding U.S. Patent No. 10,543,179 filed by HEC Pharm Co., Ltd., HEC Pharm … 28 January 2020 1:20-cv-00133 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2022-07-18 | 149 | Notice of Service | Final Invalidity Contentions Regarding U.S. Patent No. 10,543,179 filed by Novartis Pharmaceuticals Corporation… 28 January 2020 1:20-cv-00133 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2022-08-15 | 167 | Notice of Service | Final Invalidity Contentions Regarding U.S. Patent No. 10,543,179 filed by Novartis Pharmaceuticals Corporation… 28 January 2020 1:20-cv-00133 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2023-04-06 | 234 | Opinion - Memorandum Opinion | infringement of U.S. Patent No. 10,543,179 ("the '179 patent"). The '179 patent relates to…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which…quot;A claim in a patent provides the metes and bounds of the right which the patent confers on the patentee…that inform patent law." Id. The ultimate question of the proper construction of a patent is a question…x27;s construction of U.S. Patent No. 9,187,405 ("the '405 patent") in Novartis Pharmaceuticals | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
